Troponin T, N-terminal pro-B-type natriuretic peptide, and incidence of stroke: The atherosclerosis risk in communities study

Stroke

Volumn 44, Issue 4, 2013, Pages 961-967

  Folsom, Aaron R ^a   Nambi, Vijay ^b   Bell, Elizabeth J ^a   Oluleye, Oludamilola W ^a   Gottesman, Rebecca F ^c   Lutsey, Pamela L ^a   Huxley, Rachel R ^a   Ballantyne, Christie M ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Epidemiology; Natriuretic peptides; Risk factors; Stroke; Troponin

Indexed keywords

BIOLOGICAL MARKER; NATRIURETIC PEPTIDE RECEPTOR B; TROPONIN T;

ADULT; ARTICLE; ATHEROSCLEROSIS; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; LACUNAR STROKE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR;

ATHEROSCLEROSIS; BIOLOGICAL MARKERS; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MODELS, STATISTICAL; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK; RISK FACTORS; STROKE; TROPONIN T; UNITED STATES;

EID: 84876244545     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.111.000173     Document Type: Article

References (26)

1. de Lemos JA, Drazner MH, Omland T, Ayers CR, Khera A, Rohatgi A, et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA. 2010;304:2503-2512.
2. Saunders JT, Nambi V, de Lemos JA, Chambless LE, Virani SS, Boerwinkle E, et al. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation. 2011;123:1367-1376.
3. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. 2004;350:655-663.
4. Di Angelantonio E, Chowdhury R, Sarwar N, Ray KK, Gobin R, Saleheen D, et al. B-Type natriuretic peptides and cardiovascular risk: systematic review and meta-Analysis of 40 prospective studies. Circulation. 2009;120:2177-2187.
5. Rutten JH, Mattace-Raso FU, Steyerberg EW, Lindemans J, Hofman A, Wieberdink RG, et al. Amino-Terminal pro-B-Type natriuretic peptide improves cardiovascular and cerebrovascular risk prediction in the population: the Rotterdam study. Hypertension. 2010;55:785-791.
6. Kerr G, Ray G, Wu O, Stott DJ, Langhorne P. Elevated troponin after stroke: a systematic review. Cerebrovasc Dis. 2009;28:220-226.
7. Rost NS, Biffi A, Cloonan L, Chorba J, Kelly P, Greer D, et al. Brain natriuretic peptide predicts functional outcome in ischemic stroke. Stroke. 2012;43:441-445.
8. Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P. N-Terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA. 2005;293:1609-1616.
9. Winkler K, Wanner C, Drechsler C, Lilienthal J, März W, Krane V; German Diabetes and Dialysis Study Investigators. Change in N-Terminal-pro-B- Type-natriuretic-peptide and the risk of sudden death, stroke, myocardial infarction, and all-cause mortality in diabetic dialysis patients. Eur Heart J. 2008;29:2092-2099.
10. Takahashi T, Nakamura M, Onoda T, Ohsawa M, Tanno K, Itai K, et al. Predictive value of plasma B-Type natriuretic peptide for ischemic stroke: a community-based longitudinal study. Atherosclerosis. 2009;207:298-303.
11. Omland T, Sabatine MS, Jablonski KA, Rice MM, Hsia J, Wergeland R, et al.; PEACE Investigators. Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial. J Am Coll Cardiol. 2007;50:205-214.
12. Doi Y, Ninomiya T, Hata J, Hirakawa Y, Mukai N, Ikeda F, et al. N-Terminal pro-brain natriuretic peptide and risk of cardiovascular events in a Japanese community: the Hisayama study. Arterioscler Thromb Vasc Biol. 2011;31:2997-3003.
13. Hijazi Z, Oldgren J, Andersson U, Connolly SJ, Ezekowitz MD, Hohnloser SH, et al. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) substudy. Circulation. 2012;125:1605-1616.
14. Kavsak PA, Xu L, Yusuf S, McQueen MJ. High-sensitivity cardiac troponin I measurement for risk stratification in a stable high-risk population. Clin Chem. 2011;57:1146-1153.
15. Everett BM, Cook NR, Magnone MC, Bobadilla M, Kim E, Rifai N, et al. Sensitive cardiac troponin T assay and the risk of incident cardiovascular disease in women with and without diabetes mellitus: the Women's Health Study. Circulation. 2011;123:2811-2818.
16. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC Investigators. Am J Epidemiol. 1989;129: 687-702.
17. Stevens LA, Coresh J, Schmid CH, Feldman HI, Froissart M, Kusek J, et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis. 2008;51:395-406.
18. Baecke JA, Burema J, Frijters JE. A short questionnaire for the measurement of habitual physical activity in epidemiological studies. Am J Clin Nutr. 1982;36:936-942.
19. Alonso A, Agarwal SK, Soliman EZ, Ambrose M, Chamberlain AM, Prineas RJ, et al. Incidence of atrial fibrillation in whites and African-Americans: the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J. 2009;158:111-117.
20. Rosamond WD, Folsom AR, Chambless LE, Wang CH, McGovern PG, Howard G, et al. Stroke incidence and survival among middle-Aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. Stroke. 1999;30:736-743.
21. The National Survey of Stroke. National Institute of Neurological and Communicative Disorders and Stroke. Stroke. 1981;12:I1-91.
22. Ohira T, Shahar E, Chambless LE, Rosamond WD, Mosley TH Jr, Folsom AR. Risk factors for ischemic stroke subtypes: the Atherosclerosis Risk in Communities study. Stroke. 2006;37:2493-2498.
23. Desquilbet L, Mariotti F. Dose-response analyses using restricted cubic spline functions in public health research. Stat Med. 2010;29: 1037-1057.
24. Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, Obuchowski N, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology. 2010;21:128-138.
25. Chambless LE, Cummiskey CP, Cui G. Several methods to assess improvement in risk prediction models: extension to survival analysis. Stat Med. 2011;30:22-38.
26. Schnabel RB, Larson MG, Yamamoto JF, Sullivan LM, Pencina MJ, Meigs JB, et al. Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community. Circulation. 2010;121:200-207.